Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Pemetrexed disodium (ALIMTA(TM), LY231514 (MTA)) is a novel multitargeted antifolate, that inhibits at least three enzymes involved in folate metabolism and DNA synthesis. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent has shown broad antitumor activity in phase II trials in a wide variety of solid tumors, including non-small cell lung cancer, breast, colon, pancreas, bladder, head and neck, and cervical carcinomas, and is undergoing randomized phase III studies. MTA has also shown promising activity in a broad range of tumors in combination with other active agents such as gemcitabine and cisplatin. The clinical pharmacology, toxicity and clinical activity of MTA are reviewed in this report.

Original languageEnglish (US)
Pages (from-to)1335-1341
Number of pages7
JournalAnnals of Oncology
Issue number10
StatePublished - 2000


  • Multitargeted antifolate
  • Solid tumors
  • Thymidylate synthase

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors'. Together they form a unique fingerprint.

Cite this